Travere Therapeutics, Inc.

Travere Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for rare diseases, with commercial products in kidney and metabolic disorders. Its portfolio includes FILSPARI, Thiola, and Thiola EC, and it also develops earlier-stage candidates such as pegtibatinase.

−0,4 %

97,9 %

−5,2 %

+110,5 %

2.74

2.51

— Travere Therapeutics, Inc.
%
FILSPARI78% Commercial kidney-disease therapy for adults with IgA nephropathy.
Thiola / Thiola EC17% Commercial cystinuria treatments sold through specialty pharmacy channels.
License and collaboration revenue5% Milestones, royalties, and related collaboration income from partners.

Travere sells primarily to patients with rare kidney and metabolic diseases, with prescribing driven by specialists...

  • IgA nephropathy patientsprimary

    Adults with primary IgAN treated with FILSPARI through specialist prescribing and pharmacy support.

  • Cystinuria patientsprimary

    Patients with cystinuria treated with Thiola and Thiola EC to reduce cystine stone formation.

  • Specialist physiciansprimary

    Nephrologists and urologists who diagnose, prescribe, and monitor rare-disease therapies.

  • Payers and pharmacy benefit managerssecondary

    Organizations that determine reimbursement, prior authorization, and patient access conditions.

  • Partner companiessecondary

    Collaborators such as CSL Vifor that contribute milestones, royalties, and regional commercialization support.

Travere is headquartered in the United States and generates most of its commercial activity there, where FILSPARI and...

  • •United States is the core commercial market for FILSPARI and Thiola
  • •U.S. specialty pharmacy distribution supports direct patient access
  • •European exposure comes mainly through FILSPARI collaboration arrangements
  • •Commercial operations are centered on U.S. rare-disease specialists
  • •Third-party manufacturers and service providers support global supply chain

Travere’s strategy centers on commercializing FILSPARI in IgA nephropathy, defending and extending its rare-disease...

01
Grow FILSPARI in IgA nephropathyshort-term

FILSPARI is the core commercial growth driver and the main source of product revenue.

02
Protect and manage the cystinuria franchiseshort-term

Thiola and Thiola EC remain important but face generic competition and pricing pressure.

03
Advance pipeline programsmedium-term

Pipeline assets provide future growth beyond the current commercial portfolio.

04
Leverage partnerships and external manufacturingmedium-term

Outsourcing reduces the need for owned manufacturing infrastructure and supports flexibility.

Travere depends heavily on successful commercialization of FILSPARI and on physician, patient, and payer acceptance in...

high

Commercialization risk for FILSPARI

Revenue depends on physician uptake, payer coverage, and sustained market acceptance in IgAN.

Scope
Core product revenue
Materiality
high
high

Generic competition for Thiola products

Approved generics can reduce volume and pricing in the cystinuria franchise.

Scope
Thiola and Thiola EC sales
Materiality
high
high

Clinical development failure

Pipeline candidates may not achieve approval or may require additional studies.

Scope
Pegtibatinase and future candidates
Materiality
high
medium

Third-party manufacturing dependence

The company outsources API, packaging, and commercial supply, limiting direct control.

Scope
Product supply and launch execution
Materiality
medium
medium

CRO and investigator dependence

Clinical timelines and data quality rely on external research partners.

Scope
Development programs
Materiality
medium
Revenue recognition for milestones, royalties, and product sales
Can cause volatility in reported revenue and mix
Clinical trial accruals
Can shift operating expense timing
Inventory reserves
Affects gross margin and cost of goods sold
Collaboration accounting
Can materially affect non-product revenue

UroGen Pharma Ltd.

URGN · Pharmaceutical Preparations

Keros Therapeutics, Inc.

KROS · Pharmaceutical Preparations

Eton Pharmaceuticals, Inc.

ETON · Pharmaceutical Preparations

CORCEPT THERAPEUTICS INC

CORT · Pharmaceutical Preparations

Dianthus Therapeutics, Inc. /DE/

DNTH · Pharmaceutical Preparations

Organon & Co.

OGN · Pharmaceutical Preparations

: 29.4.2026